Benzinga | Feb 10, 2021 10:06AM EST

Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $85

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $57.5 to $85.